Framingham, MA – According to filings with the U.S. Securities and Exchange Commission, Alzheon is raising $6,163,716.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Martin Tolar played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Alzheon

Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is a Phase 3-ready, first-in-class, small molecule oral inhibitor of amyloid aggregation and neurotoxicity hallmarks of Alzheimer’s disease. ALZ-801 is a novel prodrug that builds on the safety and efficacy profile of the active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimer’s patients. Our clinical expertise and technology platform is focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients.

To learn more about Alzheon, visit http://alzheon.com/

Contact:
Martin Tolar, Chief Executive Officer
508-861-7709
martin.tolar@alzheon.com
https://www.linkedin.com/in/martintolar/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved